KIMS769.90

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISJUBLPHARMAINDGNONESOURCEPFIZERPOLYMEDMcap ₹30,796 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation146.590.3283.2
+ Impairment Loss / (Reversal)-1.50.00.0
+ Finance Costs47.0177.2202.5
+ Interest Income-2.3-16.2-17.7
+ Fair Value (Gains) / Losses-1.80.03.8
+ Other Non-cash Items-2.112.49.5
+ Other Reconciling Items0.0-21.7-0.5
Changes in Working Capital
+ Inventories-6.6-13.3-32.9
+ Trade Receivables — Current-40.3-93.4-168.5
+ Other Financial Assets — Current15.8153.7-12.2
+ Other Financial Assets — Non-current20.7-152.5-19.0
+ Other Current Assets-24.30.0-19.1
+ Other Non-current Assets0.1-9.63.8
+ Trade Payables — Current24.147.654.7
+ Other Financial Liabilities — Current5.00.021.1
+ Other Financial Liabilities — Non-current-1.2-22.6-21.0
+ Other Current Liabilities13.27.424.2
+ Other Non-current Liabilities0.0-2.70.0
+ Provisions — Current4.57.86.2
+ Provisions — Non-current4.20.712.4
Cash from Operating Activities
Profit Before Tax (per I/S)459.9558.1331.3273.2
+ Total Adjustments (incl. Working Capital)201.3165.1330.5
Cash from Operations (pre-tax)661.2723.2661.8
+ Income Taxes Paid140.2141.4151.0
Cash from Operating Activities521.1581.8510.8
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)647.31,008.91,427.9
+ Disp of Fixed Assets1.447.20.0
+ Disp of Investment Property0.00.015.0
+ Acq of Subsidiaries / Businesses (net)74.7178.40.0
+ Investment in Partnership Firms / LLPs0.00.08.4
+ Loans & Advances Made26.027.230.9
+ Payments on Futures / Forwards / Options / Swaps0.0350.00.0
+ Receipts on Futures / Forwards / Options / Swaps0.0415.70.0
+ Interest Received — Investing1.68.611.3
+ Other Inflows / (Outflows) — Investing-7.5-23.2-10.8
Cash from Investing Activities-752.6-1,116.2-1,451.7
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.048.8
+ Payments — Change in Ownership of Subsidiaries181.187.8155.9
+ Proceeds from Borrowings530.7877.51,538.5
+ Repayment of Borrowings17.783.7209.5
+ Payment of Lease Liabilities55.940.074.4
+ Interest Paid59.3122.90.0
+ Dividends Paid0.00.0207.2
Cash from Financing Activities216.8543.1940.3
Net Changes in Cash (pre-FX)-14.78.7-0.6
Net Changes in Cash-14.78.7-0.6
Closing Cash46.956.0
Reference Items
EBITDA640.4782.9802.0832.8
EBITDA Margin %25.6425.7920.5419.77
Free Cash Flow (CFO − Capex)-126.3-427.1-917.1-917.1
Free Cash Flow to Equity651.4-229.8
Free Cash Flow per Basic Share-3.16-10.68-22.93-22.93
Cash Flow to Net Income1.551.402.11
Cash Paid for Taxes140.2141.4151.0
Cash Paid for Interest59.3122.90.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.